J&J adds further $2 billion to $55 billion US investment
US healthcare giant Johnson & Johnson (NYSE: JNJ) has announced that it will increase its presence in North Carolina with a 160,000+ square foot dedicated manufacturing facility at Fujifilm’s (TYO: 4901) new biopharma manufacturing site in Holly Springs.
The $2 billion commitment to Fujifilm over the next 10 years - on top of a $55 billion wider investment announced in March - will expand the company’s US manufacturing capacity and create approximately 120 new jobs in North Carolina.
In the coming months, J&J also intends to share detail on plans for additional advanced manufacturing facilities in the USA, as well as the expansion of current US sites.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze